Xilio Therapeutics Inc

XLO | $1.06 0.95% 0.94% 300K

(0.0% 1d) (50.0% 1m) (-67.6% 1y) (0.0% 2d) (-4.5% 3d) (-18.0% 7d) (74.95% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 36,541,895
https://xiliotx.com
Sec Filling | Patents | 2021 employees

Xilio Therapeutics is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The company is using its proprietary geographically precise solutions (GPS) platform to rapidly engineer novel molecules, including cytokines and other biologics, that are designed to optimize their therapeutic index. These molecules are designed to localize activity within the tumor microenvironment without systemic effect, resulting in the potential to achieve enhanced anti-tumor activity. Xilio is building a pipeline of wholly-owned, tumor-selective, GPS-enabled cytokine and checkpoint inhibitor product candidates, including XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody; XTX202, a tumor-selective IL-2; XTX301, a tumor-selective IL-12; and XTX401, a tumor-selective IL-15.

cancer optical

add to watch list Paper trade email alert is off

Press-releases

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-04-01 (Crawled : 20:00) - globenewswire.com
GILD | $67.07 0.06% 0.06% 8.3M

Health Technology

| -8.03% | O: -0.08% H: 0.04% C: -1.0%
business year pipeline therapeutics financial results

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
Published: 2024-03-28 (Crawled : 11:00) - globenewswire.com
XLO | $1.06 0.95% 0.94% 300K

Professional, Scientific, and T...

| 64.32% | O: 200.47% H: 0.52% C: -43.75%
GILD | $67.07 0.06% 0.06% 8.3M

Health Technology

| -8.19% | O: 0.33% H: 0.85% C: 0.0%
million therapeutics

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
Published: 2024-03-28 (Crawled : 11:00) - globenewswire.com
XLO | $1.06 0.95% 0.94% 300K

Professional, Scientific, and T...

| 64.32% | O: 200.47% H: 0.52% C: -43.75%
GILD | $67.07 0.06% 0.06% 8.3M

Health Technology

| -8.19% | O: 0.33% H: 0.85% C: 0.0%
il-12 license program agreement

Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
Published: 2024-02-28 (Crawled : 21:00) - globenewswire.com
XLO | $1.06 0.95% 0.94% 300K

Professional, Scientific, and T...

| 59.09% | O: 0.0% H: 17.98% C: 7.42%
conference health care therapeutics

Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
Published: 2024-01-31 (Crawled : 21:00) - globenewswire.com
XLO | $1.06 0.95% 0.94% 300K

Professional, Scientific, and T...

| 61.54% | O: 2.22% H: 4.92% C: 0.84%
conference therapeutics

CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market to grow by USD 2.23 billion between 2023 and 2028, growth Driven by High target affinity and specificity of CTLA4 inhibitors - Technavio
Published: 2024-01-26 (Crawled : 02:00) - prnewswire.com
XLO | $1.06 0.95% 0.94% 300K

Professional, Scientific, and T...

| 64.06% | O: 4.69% H: 4.55% C: -2.99%
AZNCF | News | $140.3 -4.19% 1.5K

Health Technology

| 6.26% | O: 2.92% H: 1.06% C: -3.05%
BNTX | News | $88.18 -0.35% -0.35% 280K

Health Technology

| -8.68% | O: -1.35% H: 0.12% C: -0.83%
AZN | News | $71.175 0.46% 0.46% 6.1M

Health Technology

| 5.71% | O: 1.07% H: 0.1% C: -0.94%
AGEN A | $7.42 14.86% 12.94% 1.3M

Health Technology

| 977.03% | O: 3.13% H: 11.02% C: 7.11%
protein growth market

Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
Published: 2024-01-08 (Crawled : 12:30) - globenewswire.com
XLO | $1.06 0.95% 0.94% 300K

Professional, Scientific, and T...

| 22.09% | O: -2.33% H: 3.19% C: 2.38%
xtx301 pipeline therapeutics promise

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
Published: 2023-12-07 (Crawled : 12:30) - globenewswire.com
XLO | $1.06 0.95% 0.94% 300K

Professional, Scientific, and T...

| 19.3% | O: 4.53% H: 7.71% C: 0.0%
xtx101 trial therapeutics

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
Published: 2023-11-09 (Crawled : 21:00) - globenewswire.com
XLO | $1.06 0.95% 0.94% 300K

Professional, Scientific, and T...

| -34.38% | O: 9.38% H: 0.46% C: -18.29%
business pipeline therapeutics financial results

Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
Published: 2023-11-03 (Crawled : 16:00) - globenewswire.com
XLO | $1.06 0.95% 0.94% 300K

Professional, Scientific, and T...

| -58.0% | O: 0.0% H: 15.75% C: -4.0%
xtx202 tumors

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001062993-24-008004	4	2024-04-03	2024-04-02	Buy	P	3882450	3882450
0001062993-24-008004	4	2024-04-03	2024-04-02	Buy	P	485250	7345473